Skip to content

A randomized controlled study of four drugs combined with aerosol inhalation of heparin, acetylcysteine, budesonide and ipratropium bromide in promoting the absorption of COVID-19 pneumonia

A randomized controlled study of four drugs combined with aerosol inhalation of heparin, acetylcysteine, budesonide and ipratropium bromide in promoting the absorption of COVID-19 pneumonia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300073871
Enrollment
Unknown
Registered
2023-07-24
Start date
2023-08-28
Completion date
Unknown
Last updated
2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 pneumonia

Interventions

Experimental group:Nebulized inhalation of heparin, acetylcysteine, budesonide and ipratropium bromide
Control Group:Routinely treatment for COVID-19

Sponsors

Army Medical Center (Daping hospital), Army Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Age: 18-80 years old; 2. Medium and severe patients with novel coronavirus who meet the diagnostic criteria of the Diagnosis and Treatment Protocol for novel Coronavirus infection (trial version 10); 3. Onset time < 1 month; 4. Chest CT showed the characteristic manifestations of COVID-19 pneumonia: multiple small spot shadows and interstitial changes, especially in the outer band of the lung; Multiple ground glass and infiltration shadows in both lungs; In severe cases, lung consolidation occurs; 5. Ability to receive aerosol inhalation therapy; 6. Agree to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Pregnant women; 2. Symptoms of hemoptysis; 3. Allergic/intolerant to experimental drugs; 4. Severe respiratory failure requiring invasive mechanical ventilation; 5. The presence of tracheotomy and other conditions can not cooperate with atomization; 6. Patients with underlying diseases with severe interstitial lung disease (lung function DLCOS < 50% of expected value); 7. Patients with coagulation dysfunction (meet any condition) : Six items of coagulation show hypocoagulation state; Platelet < 50×10^9/L; Bleeding from the skin or other organs; 8. Patients with pulmonary edema complicated by heart failure; 9. Other life-threatening complications: severe liver and kidney damage, uncontrolled malignant tumors, etc.; 10. Patients participating in other clinical trials; 11. Other reasons are not considered appropriate for clinical trials.

Design outcomes

Primary

MeasureTime frame
Percentage of lung lesion resolution on the eighth day in hospital;

Secondary

MeasureTime frame
Improvement rate of oxygenation index;Oxygen saturation of the finger pulse;Hospital stays;Cost of hospital admission;

Countries

China

Contacts

Public ContactGuoqiang Cao

Army Medical Center (Daping hospital), Army Medical University

cgq1963@163.com+86 135 9427 6006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026